AEON Biopharma, Inc. financial data

Symbol
AEON on NYSE
Location
5 Park Plaza, Suite 1750, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 62.3 % +12.5%
Return On Equity -58.6 %
Return On Assets -20.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.16M shares -97.1%
Common Stock, Shares, Outstanding 11.5M shares -70.5%
Common Stock, Value, Issued 9K USD +125%
Weighted Average Number of Shares Outstanding, Basic 11.1M shares +1954%
Weighted Average Number of Shares Outstanding, Diluted 11.1M shares +1954%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.9M USD -76%
Operating Income (Loss) -11.1M USD -103%
Nonoperating Income (Expense) 9.5M USD -122%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.64M USD -104%
Net Income (Loss) Attributable to Parent -1.64M USD -104%
Earnings Per Share, Basic 3 USD/shares
Earnings Per Share, Diluted -1 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.44M USD +145%
Assets, Current 10.3M USD +155%
Property, Plant and Equipment, Net 200K USD -29.1%
Operating Lease, Right-of-Use Asset 1.17M USD -16.6%
Other Assets, Noncurrent 29K USD 0%
Assets 11.7M USD +103%
Accounts Payable, Current 3.91M USD +28.9%
Employee-related Liabilities, Current 546K USD -56.3%
Liabilities, Current 9.13M USD -12.5%
Operating Lease, Liability, Noncurrent 1.02M USD -19.2%
Liabilities 27.5M USD -18.3%
Retained Earnings (Accumulated Deficit) -429M USD -0.38%
Stockholders' Equity Attributable to Parent -15.9M USD +43.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -28.6M USD +81.3%
Liabilities and Equity 11.7M USD +103%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.91M USD +8.04%
Net Cash Provided by (Used in) Financing Activities 18.3M USD +267%
Common Stock, Shares Authorized 1.04B shares +108%
Common Stock, Shares, Issued 11.5M shares -70.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.4M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.44M USD +145%
Deferred Tax Assets, Valuation Allowance 59.6M USD +10.3%
Deferred Tax Assets, Gross 61M USD +12.7%
Operating Lease, Liability 1.26M USD -9.6%
Payments to Acquire Property, Plant, and Equipment 4K USD
Lessee, Operating Lease, Liability, to be Paid 1.39M USD -12%
Property, Plant and Equipment, Gross 506K USD +0.8%
Operating Lease, Liability, Current 242K USD +80.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 307K USD +75.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 297K USD +86.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 132K USD -29.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 318K USD +7.07%
Deferred Tax Assets, Operating Loss Carryforwards 36M USD +25.7%
Unrecognized Tax Benefits 16.1M USD +9.85%
Lessee, Operating Lease, Liability, to be Paid, Year Four 329K USD +7.17%
Operating Lease, Payments 31K USD -61.3%
Depreciation, Depletion and Amortization 19K USD -24%
Deferred Tax Assets, Net of Valuation Allowance 1.43M USD +831%
Share-based Payment Arrangement, Expense 1.6M USD -5.88%